Heralding a new paradigm in 3D tumor modeling

Biomaterials

Volumn 108, Issue , 2016, Pages 197-213

  Fong, Eliza L S ^a   Harrington, Daniel A ^b   Farach Carson, Mary C ^b   Yu, Hanry ^a,c,d,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b RICE UNIVERSITY   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

3D tumor models; Cancer; Organoids; Patient derived xenografts; Tumor heterogeneity; Tumor microenvironment

Indexed keywords

CELL CULTURE; CELL ENGINEERING; DISEASES; ENDOTHELIAL CELLS; ENZYME ACTIVITY; FAILURE ANALYSIS;

3D TUMOR MODELS; CANCER; ORGANOIDS; PATIENT-DERIVED XENOGRAFTS; TUMOR HETEROGENEITY; TUMOR MICROENVIRONMENT;

TUMORS;

ADIPOCYTE; CANCER CELL CULTURE; CANCER CELL LINE; CELL HETEROGENEITY; COCULTURE; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FIBROBLAST; GENETIC HETEROGENEITY; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MOLECULAR EVOLUTION; NONHUMAN; PERICYTE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA; SYNTHETIC BIOLOGY; THREE DIMENSIONAL IMAGING; TISSUE EXPANSION; TISSUE PERFUSION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR XENOGRAFT; VASCULAR ENDOTHELIAL CELL; VASCULARIZATION; ANIMAL; BATCH CELL CULTURE; DEVICES; EQUIPMENT DESIGN; EXPERIMENTAL NEOPLASM; MULTICELLULAR SPHEROID; PATHOLOGY; PROCEDURES; THREE DIMENSIONAL PRINTING; TISSUE ENGINEERING; TISSUE SCAFFOLD; TRENDS; TUMOR CELL CULTURE;

ANIMALS; BATCH CELL CULTURE TECHNIQUES; EQUIPMENT DESIGN; HUMANS; NEOPLASMS, EXPERIMENTAL; PRINTING, THREE-DIMENSIONAL; SPHEROIDS, CELLULAR; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TUMOR CELLS, CULTURED;

EID: 84987949113     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.08.052     Document Type: Review

References (205)

1. [1] Toniatti, C., Jones, P., Graham, H., Pagliara, B., Draetta, G., Oncology drug discovery: planning a turnaround. Cancer Discov. 4 (2014), 397–404.
2. [2] Kamb, A., What's wrong with our cancer models?. Nat. Rev. Drug Discov. 4 (2005), 161–165.
3. [3] Rubin, E.H., Gilliland, D.G., Drug development and clinical trials–the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9 (2012), 215–222.
4. [4] Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
5. [5] Fischbach, C., Chen, R., Matsumoto, T., Schmelzle, T., Brugge, J.S., Polverini, P.J., et al. Engineering tumors with 3D scaffolds. Nat. methods 4 (2007), 855–860.
6. [6] Fong, E.L., Lamhamedi-Cherradi, S.E., Burdett, E., Ramamoorthy, V., Lazar, A.J., Kasper, F.K., et al. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6500–6505.
7. [7] Petersen, O.W., Ronnov-Jessen, L., Howlett, A.R., Bissell, M.J., Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 9064–9068.
8. [8] Shoemaker, R.H., The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6 (2006), 813–823.
9. [9] Gillet, J.P., Calcagno, A.M., Varma, S., Marino, M., Green, L.J., Vora, M.I., et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 18708–18713.
10. [10] FANTOM Consortium and the RIKEN PMI and CLST (DGT), A.R. Forrest, H. Kawaji, M. Rehli, J.K. Baillie, M.J. de Hoon, et al., Nature 507 (7493), 2014, 462-470 (PMID 24670764).
11. [11] Sia, D., Moeini, A., Labgaa, I., Villanueva, A., The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics 16 (2015), 1671–1683.
12. [12] Yap, T.A., Gerlinger, M., Futreal, P.A., Pusztai, L., Swanton, C., Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med., 4, 2012 127ps10.
13. [13] Ledford, H., US cancer institute to overhaul tumour cell lines. Nature, 530, 2016, 391.
14. [14] Hidalgo, M., Amant, F., Biankin, A.V., Budinska, E., Byrne, A.T., Caldas, C., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4 (2014), 998–1013.
15. [15] Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
16. [16] Gao, D., Vela, I., Sboner, A., Iaquinta, P.J., Karthaus, W.R., Gopalan, A., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159 (2014), 176–187.
17. [17] van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
18. [18] Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
19. [19] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
20. [20] McMillin, D.W., Negri, J.M., Mitsiades, C.S., The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12 (2013), 217–228.
21. [21] Park, J.H., Richards, C.H., McMillan, D.C., Horgan, P.G., Roxburgh, C.S., The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncology/ESMO 25 (2014), 644–651.
22. [22] Erkan, M., Michalski, C.W., Rieder, S., Reiser-Erkan, C., Abiatari, I., Kolb, A., et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 6 (2008), 1155–1161.
23. [23] Yanagisawa, N., Li, R., Rowley, D., Liu, H., Kadmon, D., Miles, B.J., et al. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum. Pathol. 38 (2007), 1611–1620.
24. [24] Lu, P., Weaver, V.M., Werb, Z., The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196 (2012), 395–406.
25. [25] Theocharis, A.D., Skandalis, S.S., Gialeli, C., Karamanos, N.K., Extracellular matrix structure. Adv. Drug Deliv. Rev. 97 (2016), 4–27.
26. [26] Farach-Carson, M.C., Warren, C.R., Harrington, D.A., Carson, D.D., Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol. J. Int. Soc. Matrix Biol. 34 (2014), 64–79.
27. [27] Bonnans, C., Chou, J., Werb, Z., Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15 (2014), 786–801.
28. [28] Schafer, M., Werner, S., Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 9 (2008), 628–638.
29. [29] Dvorak, H.F., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315 (1986), 1650–1659.
30. [30] Desmouliere, A., Guyot, C., Gabbiani, G., The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol. 48 (2004), 509–517.
31. [31] Tuxhorn, J.A., Ayala, G.E., Smith, M.J., Smith, V.C., Dang, T.D., Rowley, D.R., Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 8 (2002), 2912–2923.
32. [32] Frantz, C., Stewart, K.M., Weaver, V.M., The extracellular matrix at a glance. J. Cell Sci. 123 (2010), 4195–4200.
33. [33] Grindel, B.J., Martinez, J.R., Pennington, C.L., Muldoon, M., Stave, J., Chung, L.W., et al. Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior. Matrix Biol. J. Int. Soc. Matrix Biol. 36 (2014), 64–76.
34. [34] Eke, I., Cordes, N., Focal adhesion signaling and therapy resistance in cancer. Semin. Cancer Biol. 31 (2015), 65–75.
35. [35] Holle, A.W., Young, J.L., Spatz, J.P., In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Adv. drug Deliv. Rev. 97 (2016), 270–279.
36. [36] Singha, N.C., Nekoroski, T., Zhao, C., Symons, R., Jiang, P., Frost, G.I., et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol. Cancer Ther. 14 (2015), 523–532.
37. [37] Bourguignon, L.Y., Peyrollier, K., Xia, W., Gilad, E., Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J. Biol. Chem. 283 (2008), 17635–17651.
38. [38] Bourguignon, L.Y., Shiina, M., Li, J.J., Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv. Cancer Res. 123 (2014), 255–275.
39. [39] Damiano, J.S., Integrins as novel drug targets for overcoming innate drug resistance. Curr. Cancer Drug Targets 2 (2002), 37–43.
40. [40] Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., Takeyama, H., Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 7 (2015), 2443–2458.
41. [41] Mehner, C., Radisky, D.C., Triggering the landslide: the tumor-promotional effects of myofibroblasts. Exp. Cell Res. 319 (2013), 1657–1662.
42. [42] Radisky, D.C., Kenny, P.A., Bissell, M.J., Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?. J. Cell. Biochem. 101 (2007), 830–839.
43. [43] Orimo, A., Weinberg, R.A., Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 6 (2007), 618–619.
44. [44] Ishii, G., Ochiai, A., Neri, S., Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv. Drug Deliv. Rev. 99:Pt B (2016), 186–196 (Pubmed ID 26278673).
45. [45] Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121 (2005), 335–348.
46. [46] Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J.F., Harrington, K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9 (2007), 1392–1400.
47. [47] Mertens, J.C., Fingas, C.D., Christensen, J.D., Smoot, R.L., Bronk, S.F., Werneburg, N.W., et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 73 (2013), 897–907.
48. [48] Carmeliet, P., Jain, R.K., Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10 (2011), 417–427.
49. [49] Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
50. [50] Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., Comoglio, P.M., Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003), 347–361.
51. [51] Bottaro, D.P., Liotta, L.A., Cancer: out of air is not out of action. Nature 423 (2003), 593–595.
52. [52] Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11 (2011), 393–410.
53. [53] Arjaans, M., Schroder, C.P., Oosting, S.F., Dafni, U., Kleibeuker, J.E., de Vries, E.G., VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 7:16 (2016), 21247–21258 (Pubmed ID 26789111).
54. [54] Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
55. [55] Meng, M.B., Zaorsky, N.G., Deng, L., Wang, H.H., Chao, J., Zhao, L.J., et al. Pericytes: a double-edged sword in cancer therapy. Future Oncol. 11 (2015), 169–179.
56. [56] Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002), 991–998.
57. [57] Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004), 329–360.
58. [58] Sharma, P., Wagner, K., Wolchok, J.D., Allison, J.P., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11 (2011), 805–812.
59. [59] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
60. [60] Nieman, K.M., Romero, I.L., Van Houten, B., Lengyel, E., Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim. Biophys. Acta 1831 (2013), 1533–1541.
61. [61] Ouchi, N., Parker, J.L., Lugus, J.J., Walsh, K., Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11 (2011), 85–97.
62. [62] Bochet, L., Lehuede, C., Dauvillier, S., Wang, Y.Y., Dirat, B., Laurent, V., et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73 (2013), 5657–5668.
63. [63] Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71 (2011), 2455–2465.
64. [64] Gazi, E., Gardner, P., Lockyer, N.P., Hart, C.A., Brown, M.D., Clarke, N.W., Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J. Lipid Res. 48 (2007), 1846–1856.
65. [65] Munson, J.M., Shieh, A.C., Interstitial fluid flow in cancer: implications for disease progression and treatment. Cancer Manag. Res. 6 (2014), 317–328.
66. [66] Chang, S.F., Chang, C.A., Lee, D.Y., Lee, P.L., Yeh, Y.M., Yeh, C.R., et al. Tumor cell cycle arrest induced by shear stress: roles of integrins and Smad. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 3927–3932.
67. [67] Fleury, M.E., Boardman, K.C., Swartz, M.A., Autologous morphogen gradients by subtle interstitial flow and matrix interactions. Biophys. J. 91 (2006), 113–121.
68. [68] Munson, J.M., Bellamkonda, R.V., Swartz, M.A., Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Cancer Res. 73 (2013), 1536–1546.
69. [69] Rutkowski, J.M., Swartz, M.A., A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol. 17 (2007), 44–50.
70. [70] Shields, J.D., Fleury, M.E., Yong, C., Tomei, A.A., Randolph, G.J., Swartz, M.A., Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11 (2007), 526–538.
71. [71] Wang, F., Weaver, V.M., Petersen, O.W., Larabell, C.A., Dedhar, S., Briand, P., et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 14821–14826.
72. [72] Benton, G., Arnaoutova, I., George, J., Kleinman, H.K., Koblinski, J., Matrigel: from discovery and ECM mimicry to assays and models for cancer research. Adv. Drug Deliv. Rev. 79–80 (2014), 3–18.
73. [73] Yeung, T.M., Gandhi, S.C., Wilding, J.L., Muschel, R., Bodmer, W.F., Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 3722–3727.
74. [74] Conklin, M.W., Keely, P.J., Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adhesion Migr. 6 (2012), 249–260.
75. [75] Barron, D.A., Rowley, D.R., The reactive stroma microenvironment and prostate cancer progression. Endocrine Related cancer 19 (2012), R187–R204.
76. [76] Cheung, K.J., Gabrielson, E., Werb, Z., Ewald, A.J., Collective invasion in breast cancer requires a conserved basal epithelial program. Cell. 155 (2013), 1639–1651.
77. [77] Riching, K.M., Cox, B.L., Salick, M.R., Pehlke, C., Riching, A.S., Ponik, S.M., et al. 3D collagen alignment limits protrusions to enhance breast cancer cell persistence. Biophys. J. 107 (2014), 2546–2558.
78. [78] Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906.
79. [79] Lang, N.R., Skodzek, K., Hurst, S., Mainka, A., Steinwachs, J., Schneider, J., et al. Biphasic response of cell invasion to matrix stiffness in three-dimensional biopolymer networks. Acta Biomater. 13 (2015), 61–67.
80. [80] Cassereau, L., Miroshnikova, Y.A., Ou, G., Lakins, J., Weaver, V.M., A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype. J. Biotechnol. 193 (2015), 66–69.
81. [81] Dunne, L.W., Huang, Z., Meng, W., Fan, X., Zhang, N., Zhang, Q., et al. Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments. Biomaterials 35 (2014), 4940–4949.
82. [82] Lu, W.D., Zhang, L., Wu, C.L., Liu, Z.G., Lei, G.Y., Liu, J., et al. Development of an acellular tumor extracellular matrix as a three-dimensional scaffold for tumor engineering. PLoS One, 9, 2014, e103672.
83. [83] Mishra, D.K., Thrall, M.J., Baird, B.N., Ott, H.C., Blackmon, S.H., Kurie, J.M., et al. Human lung cancer cells grown on acellular rat lung matrix create perfusable tumor nodules. Ann. Thorac. Surg. 93 (2012), 1075–1081.
84. [84] Moll, C., Reboredo, J., Schwarz, T., Appelt, A., Schurlein, S., Walles, H., et al. Tissue engineering of a human 3D in vitro tumor test system. J. Vis. Exp.(78), 2013 (Pubmed ID 23963401).
85. [85] Engel, B.J., Constantinou, P.E., Sablatura, L.K., Doty, N.J., Carson, D.D., Farach-Carson, M.C., et al. Multilayered, hyaluronic acid-based hydrogel formulations suitable for automated 3D high throughput drug screening of Cancer-Stromal cell cocultures. Adv. Healthc. Mater 4 (2015), 1664–1674.
86. [86] Fong, E.L., Martinez, M., Yang, J., Mikos, A.G., Navone, N.M., Harrington, D.A., et al. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol. Pharm. 11 (2014), 2040–2050.
87. [87] Fong, E.L., Wan, X., Yang, J., Morgado, M., Mikos, A.G., Harrington, D.A., et al. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77 (2016), 164–172.
88. [88] Gurski, L.A., Xu, X., Labrada, L.N., Nguyen, N.T., Xiao, L., van Golen, K.L., et al. Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels. PLoS One, 7, 2012, e50075.
89. [89] Gurski, L.A., Jha, A.K., Zhang, C., Jia, X., Farach-Carson, M.C., Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 30 (2009), 6076–6085.
90. [90] Xu, X., Farach-Carson, M.C., Jia, X., Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol. Adv. 32 (2014), 1256–1268.
91. [91] Toole, B.P., Hascall, V.C., Hyaluronan and tumor growth. Am. J. Pathol. 161 (2002), 745–747.
92. [92] Xu, X., Gurski, L.A., Zhang, C., Harrington, D.A., Farach-Carson, M.C., Jia, X., Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids. Biomaterials 33 (2012), 9049–9060.
93. [93] Pan, T., Fong, E.L., Martinez, M., Harrington, D.A., Lin, S.H., Farach-Carson, M.C., et al. Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Lett. 365 (2015), 89–95.
94. [94] Blehm, B.H., Jiang, N., Kotobuki, Y., Tanner, K., Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. Biomaterials 56 (2015), 129–139.
95. [95] Gombotz, W.R., Wang, G.H., Horbett, T.A., Hoffman, A.S., Protein adsorption to poly(ethylene oxide) surfaces. J. Biomed. Mater. Res. 25 (1991), 1547–1562.
96. [96] Gill, B.J., West, J.L., Modeling the tumor extracellular matrix: tissue engineering tools repurposed towards new frontiers in cancer biology. J. Biomechan. 47 (2014), 1969–1978.
97. [97] Loessner, D., Stok, K.S., Lutolf, M.P., Hutmacher, D.W., Clements, J.A., Rizzi, S.C., Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 31 (2010), 8494–8506.
98. [98] Wang, C., Tong, X., Yang, F., Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels. Mol. Pharm. 11 (2014), 2115–2125.
99. [99] Raza, A., Ki, C.S., Lin, C.C., The influence of matrix properties on growth and morphogenesis of human pancreatic ductal epithelial cells in 3D. Biomaterials 34 (2013), 5117–5127.
100. [100] Schwartz, M.P., Rogers, R.E., Singh, S.P., Lee, J.Y., Loveland, S.G., Koepsel, J.T., et al. A quantitative comparison of human HT-1080 fibrosarcoma cells and primary human dermal fibroblasts identifies a 3D migration mechanism with properties unique to the transformed phenotype. PLoS One, 8, 2013, e81689.
101. [101] Singh, S.P., Schwartz, M.P., Lee, J.Y., Fairbanks, B.D., Anseth, K.S., A peptide functionalized poly(ethylene glycol) (PEG) hydrogel for investigating the influence of biochemical and biophysical matrix properties on tumor cell migration. Biomater. Sci. 2 (2014), 1024–1034.
102. [102] Lutolf, M.P., Lauer-Fields, J.L., Schmoekel, H.G., Metters, A.T., Weber, F.E., Fields, G.B., et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 5413–5418.
103. [103] Pradhan, S., Farach-Carson, M.C., Mining the extracellular matrix for tissue engineering applications. Regen. Med. 5 (2010), 961–970.
104. [104] Grindel, B., Li, Q., Arnold, R., Petros, J., Zayzafoon, M., Muldoon, M., et al. Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients. Oncotarget 7 (2016), 10433–10447.
105. [105] Xia, L., Sakban, R.B., Qu, Y., Hong, X., Zhang, W., Nugraha, B., et al. Tethered spheroids as an in vitro hepatocyte model for drug safety screening. Biomaterials 33 (2012), 2165–2176.
106. [106] Nugraha, B., Hong, X., Mo, X., Tan, L., Zhang, W., Chan, P.M., et al. Galactosylated cellulosic sponge for multi-well drug safety testing. Biomaterials 32 (2011), 6982–6994.
107. [107] Burdett, E., Kasper, F.K., Mikos, A.G., Ludwig, J.A., Engineering tumors: a tissue engineering perspective in cancer biology. Tissue engineering Part B. Reviews 16 (2010), 351–359.
108. [108] Majety, M., Pradel, L.P., Gies, M., Ries, C.H., Fibroblasts influence survival and therapeutic response in a 3D Co-Culture model. PLoS One, 10, 2015, e0127948.
109. [109] Jaganathan, H., Gage, J., Leonard, F., Srinivasan, S., Souza, G.R., Dave, B., et al. Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation. Sci. Rep., 4, 2014, 6468.
110. [110] Yip, D., Cho, C.H., A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem. Biophys. Res. Commun. 433 (2013), 327–332.
111. [111] Dolznig, H., Rupp, C., Puri, C., Haslinger, C., Schweifer, N., Wieser, E., et al. Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am. J. Pathol. 179 (2011), 487–501.
112. [112] Sieh, S., Lubik, A.A., Clements, J.A., Nelson, C.C., Hutmacher, D.W., Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 6 (2010), 181–188.
113. [113] Sieh, S., Taubenberger, A.V., Lehman, M.L., Clements, J.A., Nelson, C.C., Hutmacher, D.W., Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone 63 (2014), 121–131.
114. [114] Subia, B., Dey, T., Sharma, S., Kundu, S.C., Target specific delivery of anticancer drug in silk fibroin based 3D distribution model of bone-breast cancer cells. ACS Appl. Mater. Interfaces 7 (2015), 2269–2279.
115. [115] Zhang, W., Lee, W.Y., Siegel, D.S., Tolias, P., Zilberberg, J., Patient-specific 3D microfluidic tissue model for multiple myeloma. Tissue Eng. Part C Methods 20 (2014), 663–670.
116. [116] Sung, K.E., Yang, N., Pehlke, C., Keely, P.J., Eliceiri, K.W., Friedl, A., et al. Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. Integr. Biol. (Camb) 3 (2011), 439–450.
117. [117] Choi, Y., Hyun, E., Seo, J., Blundell, C., Kim, H.C., Lee, E., et al. A microengineered pathophysiological model of early-stage breast cancer. Lab. Chip 15 (2015), 3350–3357.
118. [118] Bischel, L.L., Beebe, D.J., Sung, K.E., Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure. BMC cancer, 15, 2015, 12.
119. [119] Chwalek, K., Bray, L.J., Werner, C., Tissue-engineered 3D tumor angiogenesis models: potential technologies for anti-cancer drug discovery. Adv. Drug Deliv. Rev. 79–80 (2014), 30–39.
120. [120] Marcola, M., Rodrigues, C.E., Endothelial progenitor cells in tumor angiogenesis: another brick in the wall. Stem Cells Int., 2015, 2015, 832649.
121. [121] Seano, G., Chiaverina, G., Gagliardi, P.A., di Blasio, L., Sessa, R., Bussolino, F., et al. Modeling human tumor angiogenesis in a three-dimensional culture system. Blood, 121, 2013 e129–37.
122. [122] Benton, G., DeGray, G., Kleinman, H.K., George, J., Arnaoutova, I., In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening. PLoS One, 10, 2015, e0123312.
123. [123] Correa de Sampaio, P., Auslaender, D., Krubasik, D., Failla, A.V., Skepper, J.N., Murphy, G., et al. A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One, 7, 2012, e30753.
124. [124] Ingthorsson, S., Sigurdsson, V., Fridriksdottir, A. Jr., Jonasson, J.G., Kjartansson, J., Magnusson, M.K., et al. Endothelial cells stimulate growth of normal and cancerous breast epithelial cells in 3D culture. BMC Res. Notes, 3, 2010, 184.
125. [125] Nyga, A., Loizidou, M., Emberton, M., Cheema, U., A novel tissue engineered three-dimensional in vitro colorectal cancer model. Acta Biomater. 9 (2013), 7917–7926.
126. [126] Szot, C.S., Buchanan, C.F., Freeman, J.W., Rylander, M.N., In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors. Tissue Eng. Part C Methods 19 (2013), 864–874.
127. [127] Chwalek, K., Tsurkan, M.V., Freudenberg, U., Werner, C., Glycosaminoglycan-based hydrogels to modulate heterocellular communication in in vitro angiogenesis models. Sci. Rep., 4, 2014, 4414.
128. [128] Bray, L.J., Binner, M., Holzheu, A., Friedrichs, J., Freudenberg, U., Hutmacher, D.W., et al. Multi-parametric hydrogels support 3D in vitro bioengineered microenvironment models of tumour angiogenesis. Biomaterials 53 (2015), 609–620.
129. [129] Chung, S., Sudo, R., Mack, P.J., Wan, C.R., Vickerman, V., Kamm, R.D., Cell migration into scaffolds under co-culture conditions in a microfluidic platform. Lab. Chip 9 (2009), 269–275.
130. [130] Shin, Y., Han, S., Jeon, J.S., Yamamoto, K., Zervantonakis, I.K., Sudo, R., et al. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels. Nat. Protoc. 7 (2012), 1247–1259.
131. [131] Bai, J., Tu, T.Y., Kim, C., Thiery, J.P., Kamm, R.D., Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment. Oncotarget 6 (2015), 36603–36614.
132. [132] Jeon, J.S., Zervantonakis, I.K., Chung, S., Kamm, R.D., Charest, J.L., In vitro model of tumor cell extravasation. PLoS One, 8, 2013, e56910.
133. [133] Zervantonakis, I.K., Hughes-Alford, S.K., Charest, J.L., Condeelis, J.S., Gertler, F.B., Kamm, R.D., Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 13515–13520.
134. [134] Chan, J.M., Zervantonakis, I.K., Rimchala, T., Polacheck, W.J., Whisler, J., Kamm, R.D., Engineering of in vitro 3D capillary beds by self-directed angiogenic sprouting. PLoS One, 7, 2012, e50582.
135. [135] Kim, S., Lee, H., Chung, M., Jeon, N.L., Engineering of functional, perfusable 3D microvascular networks on a chip. Lab. Chip 13 (2013), 1489–1500.
136. [136] Harris, T.J., Drake, C.G., Primer on tumor immunology and cancer immunotherapy. J. Immunother. cancer, 1, 2013, 12.
137. [137] Crusz, S.M., Balkwill, F.R., Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol. 12 (2015), 584–596.
138. [138] Alonso-Nocelo, M., Abuin, C., Lopez-Lopez, R., de la Fuente, M., Development and characterization of a three-dimensional co-culture model of tumor T cell infiltration. Biofabrication, 8, 2016, 025002.
139. [139] Shalapour, S., Karin, M., Immunity, inflammation, and cancer: an eternal fight between good and evil. J. Clin. Investig. 125 (2015), 3347–3355.
140. [140] Chimal-Ramirez, G.K., Espinoza-Sanchez, N.A., Utrera-Barillas, D., Benitez-Bribiesca, L., Velazquez, J.R., Arriaga-Pizano, L.A., et al. MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness. BioMed Res. Int., 2013, 2013, 279505.
141. [141] Phan-Lai, V., Florczyk, S.J., Kievit, F.M., Wang, K., Gad, E., Disis, M.L., et al. Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. Biomacromolecules 14 (2013), 1330–1337.
142. [142] Khalil, D.N., Smith, E.L., Brentjens, R.J., Wolchok, J.D., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13 (2016), 273–290.
143. [143] Santoro, M., Lamhamedi-Cherradi, S.E., Menegaz, B.A., Ludwig, J.A., Mikos, A.G., Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10304–10309.
144. [144] Polacheck, W.J., Charest, J.L., Kamm, R.D., Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 11115–11120.
145. [145] Polacheck, W.J., German, A.E., Mammoto, A., Ingber, D.E., Kamm, R.D., Mechanotransduction of fluid stresses governs 3D cell migration. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 2447–2452.
146. [146] Wang, Y., Waters, J., Leung, M.L., Unruh, A., Roh, W., Shi, X., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512 (2014), 155–160.
147. [147] Burrell, R.A., McGranahan, N., Bartek, J., Swanton, C., The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501 (2013), 338–345.
148. [148] Saunders, N.A., Simpson, F., Thompson, E.W., Hill, M.M., Endo-Munoz, L., Leggatt, G., et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med. 4 (2012), 675–684.
149. [149] Pribluda, A., de la Cruz, C.C., Jackson, E.L., Intratumoral heterogeneity: from diversity comes resistance. Clin. cancer Res. Off. J. Am. Assoc. Cancer Res. 21 (2015), 2916–2923.
150. [150] Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008), 1801–1806.
151. [151] Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
152. [152] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
153. [153] Sottoriva, A., Spiteri, I., Piccirillo, S.G., Touloumis, A., Collins, V.P., Marioni, J.C., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 4009–4014.
154. [154] Shackleton, M., Quintana, E., Fearon, E.R., Morrison, S.J., Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138 (2009), 822–829.
155. [155] Gupta, P.B., Fillmore, C.M., Jiang, G., Shapira, S.D., Tao, K., Kuperwasser, C., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146 (2011), 633–644.
156. [156] Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481 (2012), 506–510.
157. [157] Meacham, C.E., Morrison, S.J., Tumour heterogeneity and cancer cell plasticity. Nature 501 (2013), 328–337.
158. [158] Bonnet, D., Dick, J.E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997), 730–737.
159. [159] Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994), 645–648.
160. [160] Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., et al. Identification of pancreatic cancer stem cells. Cancer Res. 67 (2007), 1030–1037.
161. [161] Prince, M.E., Sivanandan, R., Kaczorowski, A., Wolf, G.T., Kaplan, M.J., Dalerba, P., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 973–978.
162. [162] Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 3983–3988.
163. [163] Dalerba, P., Dylla, S.J., Park, I.K., Liu, R., Wang, X., Cho, R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 10158–10163.
164. [164] Kelly, P.N., Dakic, A., Adams, J.M., Nutt, S.L., Strasser, A., Tumor growth need not be driven by rare cancer stem cells. Science, 317, 2007, 337.
165. [165] Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., Morrison, S.J., Efficient tumour formation by single human melanoma cells. Nature 456 (2008), 593–598.
166. [166] Nowell, P.C., The clonal evolution of tumor cell populations. Science 194 (1976), 23–28.
167. [167] Chaffer, C.L., Brueckmann, I., Scheel, C., Kaestli, A.J., Wiggins, P.A., Rodrigues, L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 7950–7955.
168. [168] Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
169. [169] Polanska, U.M., Orimo, A., Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J. Cell. Physiol. 228 (2013), 1651–1657.
170. [170] Buckanovich, R.J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14 (2008), 28–36.
171. [171] Nawaz, S., Heindl, A., Koelble, K., Yuan, Y., Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, 28, 2015, 1621.
172. [172] Burrell, R.A., Swanton, C., Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 8 (2014), 1095–1111.
173. [173] Mullighan, C.G., Phillips, L.A., Su, X., Ma, J., Miller, C.B., Shurtleff, S.A., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322 (2008), 1377–1380.
174. [174] Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C.Y., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 (2014), 189–193.
175. [175] Siolas, D., Hannon, G.J., Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73 (2013), 5315–5319.
176. [176] Wilding, J.L., Bodmer, W.F., Cancer cell lines for drug discovery and development. Cancer Res. 74 (2014), 2377–2384.
177. [177] Daniel, V.C., Marchionni, L., Hierman, J.S., Rhodes, J.T., Devereux, W.L., Rudin, C.M., et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69 (2009), 3364–3373.
178. [178] Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9 (2012), 338–350.
179. [179] Kameya, T., Shimosato, Y., Tumuraya, M., Ohsawa, N., Nomura, T., Human gastric choriocarcinoma serially transplanted in nude mice. J. Natl. Cancer Inst. 56 (1976), 325–332.
180. [180] DeRose, Y.S., Wang, G., Lin, Y.C., Bernard, P.S., Buys, S.S., Ebbert, M.T., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17 (2011), 1514–1520.
181. [181] Loukopoulos, P., Kanetaka, K., Takamura, M., Shibata, T., Sakamoto, M., Hirohashi, S., Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29 (2004), 193–203.
182. [182] Zhao, X., Liu, Z., Yu, L., Zhang, Y., Baxter, P., Voicu, H., et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-oncology 14 (2012), 574–583.
183. [183] Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1 (2011), 508–523.
184. [184] Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
185. [185] Malaney, P., Nicosia, S.V., Dave, V., One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 344 (2014), 1–12.
186. [186] Cassidy, J.W., Caldas, C., Bruna, A., Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 75 (2015), 2963–2968.
187. [187] Aparicio, S., Hidalgo, M., Kung, A.L., Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15 (2015), 311–316.
188. [188] Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459 (2009), 262–265.
189. [189] Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H.J., van Es, J.H., et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6 (2010), 25–36.
190. [190] Huch, M., Dorrell, C., Boj, S.F., van Es, J.H., Li, V.S., van de Wetering, M., et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 494 (2013), 247–250.
191. [191] Karthaus, W.R., Iaquinta, P.J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159 (2014), 163–175.
192. [192] Sato, T., Stange, D.E., Ferrante, M., Vries, R.G., Van Es, J.H., Van den Brink, S., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141 (2011), 1762–1772.
193. [193] Weeber, F., van de Wetering, M., Hoogstraat, M., Dijkstra, K.K., Krijgsman, O., Kuilman, T., et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 13308–13311.
194. [194] Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21 (2015), 256–262.
195. [195] Cekanova, M., Rathore, K., Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des. Dev. Ther. 8 (2014), 1911–1921.
196. [196] Walrath, J.C., Hawes, J.J., Van Dyke, T., Reilly, K.M., Genetically engineered mouse models in cancer research. Adv. cancer Res. 106 (2010), 113–164.
197. [197] Bossen, C., Ingold, K., Tardivel, A., Bodmer, J.L., Gaide, O., Hertig, S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281 (2006), 13964–13971.
198. [198] Mestas, J., Hughes, C.C., Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004), 2731–2738.
199. [199] Navin, N.E., The first five years of single-cell cancer genomics and beyond. Genome Res. 25 (2015), 1499–1507.
200. [200] Di Palma, S., Bodenmiller, B., Unraveling cell populations in tumors by single-cell mass cytometry. Curr. Opin. Biotechnol. 31 (2015), 122–129.
201. [201] Giesen, C., Wang, H.A., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. methods 11 (2014), 417–422.
202. [202] Boutros, M., Heigwer, F., Laufer, C., Microscopy-based high-content screening. Cell. 163 (2015), 1314–1325.
203. [203] Valta, M.P., Zhao, H., Saar, M., Tuomela, J., Nolley, R., Linxweiler, J., et al. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clin. Exp. metastasis 33 (2016), 325–337.
204. [204] Pearson, A.T., Finkel, K.A., Warner, K.A., Nor, F., Tice, D., Martins, M.D., et al. Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget 7 (2016), 7993–8005.
205. [205] Li, J.R., Sun, C.H., Li, W., Chao, R.F., Huang, C.C., Zhou, X.J., et al. Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells. Nucleic Acids Res. 44 (2016), D944–D951.